The npt I gene in place of the T-DNA in EHA101 requires that binary plasmids that are put into the strain encode a drug resistance other than kanamycin.
32.
While the main product produced by " Streptomyces kanamyceticus " is kanamycin A, additional products are also produced, including kanamycin B, kanamycin C, kanamycin D and kanamycin X.
33.
While the main product produced by " Streptomyces kanamyceticus " is kanamycin A, additional products are also produced, including kanamycin B, kanamycin C, kanamycin D and kanamycin X.
34.
While the main product produced by " Streptomyces kanamyceticus " is kanamycin A, additional products are also produced, including kanamycin B, kanamycin C, kanamycin D and kanamycin X.
35.
While the main product produced by " Streptomyces kanamyceticus " is kanamycin A, additional products are also produced, including kanamycin B, kanamycin C, kanamycin D and kanamycin X.
36.
While the main product produced by " Streptomyces kanamyceticus " is kanamycin A, additional products are also produced, including kanamycin B, kanamycin C, kanamycin D and kanamycin X.
37.
Kanamycin is an aminoglycoside antibiotic which induces deafness through blockage of the Outer Hair Cells of the cochlea; yet it has many other effects, weakening for instance the collagen and DNA biosynthesis.
38.
MDR-TB takes longer to treat with second-line drugs ( i . e ., amikacin, kanamycin, or capreomycin ), which are more expensive and have more side-effects.
39.
PGreenII 0029 : derived from pGreenII 0000, a nos-kan cassette has been inserted into the " Hpa " I site of the Left Border, providing resistance to kanamycin during plant transformation selection.
40.
The gene in the entry plasmid ( which possesses kanamycin or zeocin resistance ) is flanked by attL sites, whereas the Gateway cassette in the destination plasmid ( which possesses ampicillin resistancy ) is flanked by attR sites.
